Nutritional Support During Induction Therapy for Esophageal Cancer

Nutritional Support in Patient Undergoing Induction Therapy for Esophageal Cancer

Patients diagnosed with esophageal cancer have difficulty eating, as the food pipe becomes obstructed by the cancer. This may impair the ability for the patient to receive appropriate calorie intake, especially during administration of chemotherapy and radiation therapy given prior to surgical resection.

A strategy is to place a feeding tube directly in the stomach or in the small bowel to have an access to the patient's gastrointestinal tract during administration of chemo radiation therapy. However, these feeding tubes may lead to adverse events, including dislodgement, infection, the tube may be plugged, etc. If these complications were to happen, patients may have their treatment delayed, may have to come to the emergency department or even be admitted. In some cases, patients may need to have a surgery performed to treat the complication. Most centres in Canada have moved away from placement of these feeding tubes due to the high incidence of complications associated with the feeding tubes placement, and due to the high efficacy from the chemoradiation therapy in shrinking the tumour, allowing for the patient to swallow.

In London, the preference from the Medical and Radiation Oncologists was to have these feeding tubes placed to avoid delay in treating the patients. There is therefore significant controversy as to what is the best approach in this patient population. Our goal is to run a feasibility randomized controlled trial studying this question.

Study Overview

• Status: Recruiting
• Conditions: Esophageal Cancer; Nutrition Aspect of Cancer
• Intervention / Treatment: Procedure: Placement of a percutaneous feeding tube; Procedure: No feeding tube placed

Detailed Description

Esophageal cancer is highly lethal. In Ontario in 2020, an estimated 900 patients were diagnosed with esophageal cancer, while 860 died from it. In Canada, the figures are 2400 diagnoses and 2260 deaths. The incidence of esophageal cancer in Canada is projected to increase over time, especially in males who are more likely to be obese and to suffer from reflux disease.

Esophageal cancer is the malignancy associated with the highest risk for malnutrition. Before their diagnosis, 80% of all patients with esophageal cancer have over 10-15% unintentional weight loss. Strategies to palliate malnutrition in cancer patients and its consequences on outcomes have been developed. In patient with severe nutritional risk, use of nutritional support for at least 10-14 days has been recommended in a non-surgical, oncology population. The European Society for Clinical Nutrition and Metabolism have recommended preoperatively enteral nutrition for 5-7 days in cancer patients undergoing major abdominal surgery. In addition, dietary counselling and oral nutritional supplement were suggested to prevent weight loss and interruption of radiotherapy on patients undergoing radiation treatments for head/neck or gastrointestinal malignancies. Routine enteral nutrition was not suggested during chemotherapy-only treatments.

The type of supplements administered may have an impact on recovery. It was shown that esophageal cancer patients receiving enriched glutamine, fibers and oligosaccharide perioperative enteral supplementation had a shorter systemic inflammatory response syndrome postoperatively and less surgical stress, which could in turn lead to reduced postoperative immunosuppressive conditions. A recent retrospective study from Taiwan did show a slightly improved 4-year overall survival rate and less mucositis on patients supported by enteral feeding tubes with esophageal squamous cell carcinoma and undergoing neoadjuvant therapy.

However, there is still equipoise in the literature and most centers in Canada have moved away from feeding tubes. At LHSC, feeding tubes were historically placed on every patient during their induction treatment. Efforts are being made to spare patients from unnecessary procedure, but patient selection is variable. Standardization of this practice is needed. A recent retrospective study evaluating the effect of surgical enteral access prior to induction treatment did not show nutritional or perioperative benefit. There was no difference in postoperative complication rates and weight loss was similar. In fact, dysphagia is felt to be significantly relieved after a single cycle of chemotherapy. Percutaneous feeding tubes may not be required on all patients during induction therapy for esophageal cancer.

Those feeding tubes are associated with high morbidity. Kidane et al have shown that 39.3% of visits to the ED after an esophagectomy are due to feeding tubes problems (dislodgement, blockage, infection). Of those ED visits for feeding tubes issues, 17% resulted to an admission. Small bowel obstruction is also associated to percutaneous feeding tube placement and selective use has been recommended. Perioperative use of feeding jejunostomy in gastroesophageal cancer has been associate with a complication rate as high as 44%. Given the related-morbidity, guidelines now recommend selective use of feeding tubes on high-risk patients after esophagectomy. When patients undergoing chemotherapy present to the emergency department with fever or infectious signs, data from the Ontario Cancer Registry show that 46% are admitted, increasing healthcare burden. At baseline, patients undergoing chemotherapy are at high risk of presenting to the emergency department or having unplanned visit to the cancer center, this figure going as high as 49% within 4 weeks of initiation of chemotherapy in comparable jurisdictions. Efforts must be made to save an already strained system.

According to the 2020 Surgical Quality Indicator Report Summary from OH-CCO, our center has the worst 30-day unplanned ED visit rate (45%, provincial mean 27%) after esophagectomy in the province of Ontario. Anecdotally, it is felt that most of those cases are related to feeding tubes complications. If these patients present to the ED due to feeding tubes concerns after an esophagectomy, it is likely they would have presented during induction treatment if they had a tube.

Alternative to feeding tubes exist (home IV hydration) which could become a less invasive and more interesting solution.

The objective of this study is to assess the feasibility of a larger randomized controlled trial evaluating unplanned visit to the ED or the outpatient clinic in patients eligible for trimodality for esophageal cancer during their induction treatment, randomized into receiving percutaneous enteral access for nutritional support versus not.

• Study Type: Interventional
• Enrollment (Estimated): 26
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Deb Lewis; Phone Number: 75685 5196858500; Email: deb.lewis@lhsc.on.ca
• Study Contact Backup: Name: Mehdi Qiabi, MD MSc; Phone Number: 519-667-6572; Email: mehdi.qiabi@lhsc.on.ca

Study Locations

• Canada
  • Ontario
    • London, Ontario, Canada, N6A 5W9
      • Recruiting
      • London Health Sciences Centre - Victoria Hospital
      • Principal Investigator: Mehdi Qiabi, MD MSc
      • Sub-Investigator: Richard A Malthaner, MD MSc
      • Sub-Investigator: Rahul Nayak, MD
      • Sub-Investigator: David Palma, MD PhD
      • Sub-Investigator: Michael Sanatani, MD
      • Sub-Investigator: Daniel Breadner, MD MSc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adult patient
• Non-cervical biopsy-proven esophageal or gastroesophageal junction (Siewert I or II) cancer
• Patient eligible for induction therapy then esophagectomy (stage Ib to III)

Exclusion Criteria:

• Impossibility to pass an endoscope beyond the tumour
• metastatic disease
• early-stage disease with either upfront esophagectomy or endoscopic resection planned
• patient refusal of the feeding tube
• inability to swallow their pill
• inability to tolerate a full fluid diet

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Percutaneous enteral access; Feeding tube, either gastrostomy (G-) tube or gastrojejunostomy (GJ-) tube (placed by Interventional Radiology) or J-tube (surgically placed)	Procedure: Placement of a percutaneous feeding tube; The standard arm will have a feeding tube placed (G-tube or GJ-tube by IR; or surgically placed J-tube)
Experimental: No percutaneous enteral access; No feeding tube placed.	Procedure: No feeding tube placed; The experimental arm will forego placement of a feeding tube.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility of the trial	The trial will be deemed feasible if 60% or more of eligible patients are recruited, 80% or more of data is collected, and 5% or less patients are lost to follow-up.	From randomization to 90-day post-operative

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of unplanned visits (ED or outpatient clinic)	Rate of unplanned visits (ED or outpatient clinic) from randomization to esophagectomy	From randomization to 90-day post-operative
Time from PET scan to beginning of induction treatment		From randomization to 90-day post-operative
Total weight loss (kilograms)	Change in kilograms from baseline measured at each visit	From randomization to 90-day post-operative
Nutritional status	Measured using serum albumin	From randomization to 90-day post-operative
Any grade adverse event rate		From randomization to 90-day post-operative
Interruption or dose-reduction of the induction treatment		From randomization to 90-day post-operative
Rate of completion of planned induction treatment		From randomization to 90-day post-operative
Quality of life using the Health Related Quality of Life Functional Assessment of Cancer Therapy - Esophageal (HRQOL FACT-E) questionnaire	Higher scores for the scales and subscales indicate better quality of life	From randomization to 90-day post-operative
Quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Oesophago-gastric 25 (EORTC QLQ-OG25) questionnaire	A high score on the functional scales or the global quality of life scale indicates a high function or high level of global quality of life, conversely a high score on a symptom scale represents a high level (severity or frequency, depending on the specific question) of the symptom in question.	From randomization to 90-day post-operative
Quality of life using the EuroQOL 5 Dimensions 3 Levels (EQ-5D-3L) questionnaire	The maximum score of 1 indicates the best health state, by contrast with the scores of individual questions, where higher scores indicate more severe or frequent problems.	From randomization to 90-day post-operative
Post-operative morbidity		From surgery to 90-day post-operative
Post-operative mortality		From surgery to 90-day post-operative

Collaborators and Investigators

• Sponsor: Mehdi Qiabi

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2022
• Primary Completion (Estimated): September 30, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: March 5, 2022
• First Submitted That Met QC Criteria: March 29, 2022
• First Posted (Actual): April 7, 2022

Study Record Updates

• Last Update Posted (Actual): April 3, 2024
• Last Update Submitted That Met QC Criteria: April 2, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: randomized controlled trial; cancer; feasibility; adverse events; enteral nutrition; esophagus; feeding tube
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Head and Neck Neoplasms; Esophageal Diseases; Esophageal Neoplasms
• Other Study ID Numbers: HSREB #120816

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No